Patents by Inventor David Roger Adams

David Roger Adams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and Their Use as PDE4 Activators
    Publication number: 20240150339
    Abstract: The present invention relates to compounds of Formulas A-D, I-IV and Z, their use as activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to these compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3?,5?-adenosine monophosphate (cAMP).
    Type: Application
    Filed: February 15, 2022
    Publication date: May 9, 2024
    Applicant: Mironid Limited
    Inventors: Julia Mary Adam, David Roger Adams
  • Compounds and their use as PDE4 activators
    Patent number: 11560373
    Abstract: The present invention relates to compounds as defined herein, which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to therapies using these activators. In particular, the invention relates to these activator compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3?,5?-adenosine monophosphate (cAMP).
    Type: Grant
    Filed: April 4, 2019
    Date of Patent: January 24, 2023
    Assignee: Mironid Limited
    Inventors: Julia Mary Adam, David Roger Adams, Santosh Shripad Kulkarni, Rahul Shripad Nandurdikar
  • Compounds and their use as PDE4 activators
    Patent number: 11046660
    Abstract: Compounds of Formula I, which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) are provided. Methods and uses of these compounds for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3?,5?-adenosine monophosphate (cAMP) are also described.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: June 29, 2021
    Assignee: Mironid Limited
    Inventors: Julia Mary Adam, David Roger Adams
  • Compounds and Their Use as PDE4 Activators
    Publication number: 20210032231
    Abstract: The present invention relates to compounds as defined herein, which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to therapies using these activators. In particular, the invention relates to these activator compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3?,5?-adenosine monophosphate (cAMP).
    Type: Application
    Filed: April 4, 2019
    Publication date: February 4, 2021
    Applicant: Mironid Limited
    Inventors: Julia Mary Adam, David Roger Adams, Santosh Shripad Kulkarni, Rahul Shripad Nandurdikar
  • COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS
    Publication number: 20200031781
    Abstract: Compounds of Formula I, which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) are provided. Methods and uses of these compounds for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3?,5?-adenosine monophosphate (cAMP) are also described.
    Type: Application
    Filed: September 28, 2017
    Publication date: January 30, 2020
    Applicant: MIRONID LIMITED
    Inventors: Julia Mary Adam, David Roger Adams
  • Stem Cell Culture Methods
    Publication number: 20120202287
    Abstract: The invention provides methods for reversibly inhibiting stem cell differentiation wherein a compound of formula (I) is contacted with a stem cell. The invention further provides a method for preparing a culture medium, a culture medium supplement and a composition comprising a compound of formula (I).
    Type: Application
    Filed: January 7, 2010
    Publication date: August 9, 2012
    Inventors: David Roger Adams, Peter Burton, Miles Douglas Houslay, Graeme Milligan, Joanne Mountford
  • Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient
    Patent number: 7763617
    Abstract: Novel pyrazolopyridine-4-yl pyridazinone derivatives serve as phosphodiesterase inhibitors and are useful compounds for use in pharmaceutical products. Specifically, the compounds of the present invention are pyrazolopyridine-4-yl pyridazinone derivatives represented by the following general formula (1): (Example: 6-(2-ethyl-7-methoxy-pyrazolo[1,5-a]pyridine-4-yl)-5-methyl-4, 5-dihydro-3(2H)-pyridazinone).
    Type: Grant
    Filed: March 6, 2006
    Date of Patent: July 27, 2010
    Assignee: Kyorin Pharmaceutical Co., Ltd.
    Inventors: Yasushi Kohno, David Roger Adams, Naoki Ando
  • Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient
    Publication number: 20080207902
    Abstract: Novel pyrazolopyridine-4-yl pyridazinone derivatives serve as phosphodiesterase inhibitors and are useful compounds for use in pharmaceutical products. Specifically, the compounds of the present invention are pyrazolopyridine-4-yl pyridazinone derivatives represented by the following general formula (1): (Example: 6-(2-ethyl-7-methoxy-pyrazolo[1,5-a]pyridine-4-yl)-5-methyl-4, 5-dihydro-3(2H)-pyridazinone).
    Type: Application
    Filed: March 6, 2006
    Publication date: August 28, 2008
    Inventors: Yasushi Kohno, David Roger Adams, Naoki Ando